<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902026000101704</article-id>
<article-id pub-id-type="doi">10.29193/rmu.42.1.15</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Octreotide de liberación prolongada y su uso en la oclusión intestinal maligna]]></article-title>
<article-title xml:lang="en"><![CDATA[Long-acting octreotide and its use in malignant intestinal obstruction]]></article-title>
<article-title xml:lang="pt"><![CDATA[Octreotida de liberação prolongada e seu uso na obstrução intestinal maligna]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Godoy]]></surname>
<given-names><![CDATA[Mateo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Papa]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Di Pietro]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Médica Uruguaya Corporación de Asistencia Médica  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<volume>42</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902026000101704&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902026000101704&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902026000101704&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La oclusión intestinal maligna es un cuadro complejo, que plantea un desafío para los equipos de cuidados paliativos. Sus síntomas generan un impacto físico y emocional en el paciente, así como en su entorno. Un deterioro acelerado suele estar asociado a un mal pronóstico de la enfermedad. Se presenta el reporte de caso de un paciente de 41 años con una oclusión maligna de intestino delgado, cuyo manejo fue dirigido por el equipo de Cuidados Paliativos. Durante el transcurso del cuadro clínico se utilizaron diferentes fármacos: analgésicos, esteroides, agentes propulsores de la motilidad gastrointestinal, así como antisecretores. Se destaca el uso de análogos de la somatostatina tanto de liberación inmediata como prolongada, obteniéndose una remisión de síntomas que permitió una estabilización clínica durante los 25 días posteriores a su administración, hasta su fallecimiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Malignant intestinal obstruction is a complex condition that poses a challenge for palliative care teams. Its symptoms have a physical and emotional impact on the patient, as well as on their environment. Rapid deterioration is usually associated with a poor prognosis of the disease. We present a case report of a 41-year-old patient with malignant small bowel obstruction, whose management was led by the Palliative Care team. During the course of the clinical condition, different drugs were used, including analgesics, steroids, gastrointestinal motility&#8211;promoting agents, and antisecretory agents. The use of somatostatin analogues, both immediate- and long-acting, is highlighted, achieving symptom remission that allowed clinical stabilisation for the 25 days following their administration, until the patient&#8217;s death.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A obstrução intestinal maligna é uma condição complexa que representa um desafio para as equipes de cuidados paliativos. Seus sintomas geram impacto físico e emocional no paciente, bem como em seu entorno. A deterioração acelerada costuma estar associada a um mau prognóstico da doença. Apresenta-se o relato de caso de um paciente de 41 anos com obstrução maligna do intestino delgado, cujo manejo foi conduzido pela equipe de Cuidados Paliativos. Durante o curso do quadro clínico, foram utilizados diferentes fármacos, incluindo analgésicos, esteroides, agentes propulsores da motilidade gastrointestinal e agentes antissecretores. Destaca-se o uso de análogos da somatostatina, tanto de liberação imediata quanto prolongada, obtendo-se remissão dos sintomas que permitiu estabilização clínica durante os 25 dias subsequentes à sua administração, até o óbito do paciente.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Oclusión maligna]]></kwd>
<kwd lng="es"><![CDATA[Cuidados paliativos]]></kwd>
<kwd lng="es"><![CDATA[Análogos de la somatostatina]]></kwd>
<kwd lng="en"><![CDATA[Malignant obstruction]]></kwd>
<kwd lng="en"><![CDATA[Palliative care]]></kwd>
<kwd lng="en"><![CDATA[Somatostatin analogues]]></kwd>
<kwd lng="pt"><![CDATA[Obstrução maligna]]></kwd>
<kwd lng="pt"><![CDATA[Cuidados paliativos]]></kwd>
<kwd lng="pt"><![CDATA[Análogos da somatostatina]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ripamonti]]></surname>
<given-names><![CDATA[CI]]></given-names>
</name>
<name>
<surname><![CDATA[Easson]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gerdes]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of malignant bowel obstruction]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2008</year>
<volume>44</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1105-15</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tuca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guell]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Losada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Codorniu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant bowel obstruction in advanced cancer patients: Epidemiology, management, and factors influencing spontaneous resolution]]></article-title>
<source><![CDATA[Cancer Manag Res]]></source>
<year>2012</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>159-69</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tóth]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tóth]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[L&#337;czi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Török]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ács]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Várbíró]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Malignant Bowel Obstruction in Patients with Gynaecological Cancer: A Systematic Review]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2024</year>
<volume>13</volume>
<numero>14</numero>
<issue>14</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muldoon]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Malignant Large Bowel Obstruction]]></article-title>
<source><![CDATA[Clin Colon Rectal Surg]]></source>
<year>2021</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>251-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Brien]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tilson]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Water absorption in experimental closed segment obstruction of the ileum in man]]></article-title>
<source><![CDATA[Am J Surg]]></source>
<year>1971</year>
<volume>121</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>96-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Periferakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tsigas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Periferakis]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Tone]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Hemes]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Periferakis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias]]></article-title>
<source><![CDATA[Curr Issues Mol Biol]]></source>
<year>2024</year>
<volume>46</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>9721-59</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rinke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wittenberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schade-Brittinger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aminossadati]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ronicke]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gress]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival]]></article-title>
<source><![CDATA[Neuroendocrinology]]></source>
<year>2016</year>
<volume>104</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-32</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ripamonti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Groff]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zecca]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[De Conno]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Casuccio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: A prospective randomized trial]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2000</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>23-34</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ripamonti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Casuccio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zecca]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Groff]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2000</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>188-91</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mystakidou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tsilika]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kalaidopoulou]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Chondros]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Georgaki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Papadimitriou]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2002</year>
<volume>22</volume>
<numero>2B</numero>
<issue>2B</issue>
<page-range>1187-92</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercadante]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tartaglia]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Octreotide for long-lasting malignant bowel obstruction: two case reports]]></article-title>
<source><![CDATA[Ann Palliat Med]]></source>
<year>2024</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>183-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Walter]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hamid]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carozza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Roche]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2024</year>
<volume>67</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>20-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mangili]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Franchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mariani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zanaboni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rabaiotti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Frigerio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Octreotide in the management of bowel obstruction in terminal ovarian cancer]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>1996</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>345-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="book">
<collab>Novartis Pharmaceuticals Canada Inc.</collab>
<source><![CDATA[Product monograph including patient medication information: MEKINIST [Internet]]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Canada ]]></publisher-loc>
<publisher-name><![CDATA[Novartis Pharmaceuticals Canada Inc.]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mariani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Blumberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Landau]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lebrun-Jezekova]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Botton]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Beatrix]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: A randomized, double-blind, placebo-controlled phase III study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2012</year>
<volume>30</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>4337-43</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Madariaga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ghoshal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dzier&#380;anowski]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Larkin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sobocki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer]]></article-title>
<source><![CDATA[Support Care Cancer]]></source>
<year>2022</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>4711-28</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha técnica Sandostatin LAR 20 mg, polvo y disolvente para suspensión inyectable [Internet]]]></source>
<year></year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[AEMPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="book">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology: Palliative Care [Internet]]]></source>
<year></year>
<publisher-loc><![CDATA[Fort Washington (PA) ]]></publisher-loc>
<publisher-name><![CDATA[National Comprehensive Cancer Network]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currow]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Agar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fazekas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hardy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[McCaffrey]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2015</year>
<volume>49</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>814-21</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanabe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wada]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ohkubo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nitta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ikezaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Takeuchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Stability of octreotide acetate decreases in a sodium bisulfate concentration-dependent manner: Compatibility study with morphine and metoclopramide injections]]></article-title>
<source><![CDATA[Eur J Hosp Pharm]]></source>
<year>2015</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>171-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
